A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma
โ Scribed by James N. Ingle; Vera J. Suman; Carl G. Kardinal; James E. Krook; James A. Mailliard; Michael H. Veeder; Charles L. Loprinzi; Robert J. Dalton; Lynn C. Hartmann; Cheryl A. Conover; Michael N. Pollak
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 110 KB
- Volume
- 85
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
โฆ Synopsis
BACKGROUND.
Tamoxifen (TAM) is generally considered the hormonal agent of choice for postmenopausal women with hormone receptor positive breast carcinoma. The somatostatin analogues, including octreotide, have demonstrated inhibition of breast carcinoma cell lines and multiple endocrinologic actions, including reduction of insulin-like growth factor I (IGF-I), a potent mitogen for breast carcinoma cells. In an attempt to improve the efficacy of TAM, this randomized trial was performed.
๐ SIMILAR VOLUMES
## BACKGROUND. Metastatic melanoma is a disease associated with a poor prognosis, and dacarbazine is still the reference agent. The authors conducted a randomized trial to test the benefit of adding tamoxifen to dacarbazine and carboplatin chemotherapy for previously untreated patients with metast
In order to test the effect of a psychological intervention on survival from cancer, 66 women with metastatic breast cancer, all receiving standard medical care, were randomly assigned into two groups; one group (n = 30) attended the psychological intervention, consisting of 35 weekly, 2 h sessions
## BACKGROUND. The purpose of this study was to evaluate the effect of breast irradiation on quality of life, including cosmetic outcome, for patients enrolled in a clinical trial. ## METHODS. Between 1984 and 1989, a randomized trial was conducted in Ontario, Canada, in which women with lymph no